A drug best known for treating diabetes and driving weight loss may also sharply reduce the risk of depression, anxiety, and substance use disorders, according to one of the largest studies ever conducted on GLP-1 medications and mental health.
Researchers from the University of Eastern Finland, Karolinska Institutet in Sweden, and Griffith University in Australia analyzed data from Swedish national health registers covering nearly 100,000 people between 2009 and 2022. More than 20,000 of those participants had used GLP-1 medications during that period. The study's design allowed scientists to compare each person's health during periods when they were taking the drugs against periods when they were not, making it easier to isolate the drug's effects.
The results, published May 4, showed that semaglutide, the active ingredient in Ozempic and Wegovy, was associated with a 44% lower risk of depression and a 38% reduction in anxiety disorders. Psychiatric-related hospital care and sick leave dropped by 42% overall during periods of semaglutide use.
The mental health benefits extended further than mood disorders. Hospital care and work absence linked to substance use disorders fell by 47% during semaglutide use. Researchers also observed a reduced risk of suicidal behavior among GLP-1 users, though the study was observational and does not establish that the drug directly causes these improvements.
The link between metabolic disease and mental health has long been recognized. Obesity and type 2 diabetes both correlate with higher rates of depression and anxiety, and people with psychiatric conditions face elevated risks of developing metabolic disease. That two-way relationship has made researchers curious about whether treating one set of conditions might relieve the other.
Professor Mark Taylor of Griffith University, one of the study's authors, said the mental health findings were not entirely surprising. An earlier Swedish register study had already found GLP-1 medications linked to lower rates of alcohol use disorder, and the new results extend that picture considerably.
Scientists are still working to understand the mechanism behind these effects. Some researchers believe GLP-1 receptors in the brain may play a direct role in mood regulation, separate from any effects on weight or blood sugar. Others point to the psychological and physiological benefits of weight loss itself, including reduced inflammation and improved sleep.
The study's scale and duration make it one of the strongest pieces of observational evidence to date. But researchers caution that randomized controlled trials will be needed before any firm conclusions can be drawn about whether semaglutide should be prescribed specifically for mental health conditions.
